Cargando…
DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines
BACKGROUND: Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment failure remains a critical issue since about 60 % of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance. METHODS: We analyzed global gene expression profiles of...
Autores principales: | Salim, Hogir, Zong, Dali, Hååg, Petra, Novak, Metka, Mörk, Birgitta, Lewensohn, Rolf, Lundholm, Lovisa, Viktorsson, Kristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565013/ https://www.ncbi.nlm.nih.gov/pubmed/26353782 http://dx.doi.org/10.1186/s12885-015-1635-9 |
Ejemplares similares
-
Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest
por: Lundholm, L, et al.
Publicado: (2013) -
EPHA2 Interacts with DNA-PK(cs) in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells
por: Kaminskyy, Vitaliy O., et al.
Publicado: (2021) -
Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells
por: Zovko, Ana, et al.
Publicado: (2016) -
Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer
por: Efazat, Ghazal, et al.
Publicado: (2016) -
Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer
por: Zong, D, et al.
Publicado: (2014)